Data / Drug companies / Venlafaxine hydrochloride
Venlafaxine hydrochloride: 48 companies and 213 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Venlafaxine hydrochloride is listed in the FDA National Drug Code Directory by 48 companies, with 213 products in commercial distribution. 208 of the products (97.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, extended release; tablet; tablet, extended release, and the newest product started marketing on November 2, 2026.
The request: Get every company that lists venlafaxine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 48
- Products
- 213
- Generic (ANDA) products
- 208 (97.7%)
- Application numbers
- 22
- Routes
- Oral
- Brand names
- Venlafaxine, Venlafaxine, Effexor XR
- openFDA record search
- api.fda.gov
Companies that list venlafaxine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 19 | capsule, extended release; tablet | Generic drugs (ANDA) | September 7, 2022 |
| Bryant Ranch Prepack | 15 | capsule, extended release; tablet | Generic drugs (ANDA) | September 25, 2023 |
| Remedyrepack Inc. | 13 | capsule, extended release; tablet | Generic drugs (ANDA) | April 24, 2026 |
| Advanced Rx of Tennessee, LLC | 10 | capsule, extended release; tablet, extended release | Generic drugs (ANDA) | April 9, 2026 |
| NuCare Pharmaceuticals,Inc. | 9 | capsule, extended release | Generic drugs (ANDA) | September 25, 2023 |
| Aurobindo Pharma Limited | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | November 23, 2011 |
| Dr. Reddy's Laboratories Limited | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | June 1, 2011 |
| Teva Pharmaceuticals USA, Inc. | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | July 1, 2010 |
| Zydus Lifesciences Limited | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | June 1, 2011 |
| Coupler LLC | 5 | capsule, extended release; tablet | Generic drugs (ANDA) | November 2, 2026 |
| Preferred Pharmaceuticals Inc. | 5 | capsule, extended release | Generic drugs (ANDA) | February 27, 2025 |
| Rising Pharma Holdings, Inc. | 5 | tablet | Generic drugs (ANDA) | April 7, 2010 |
| Yaopharma Co., Ltd. | 5 | tablet | Generic drugs (ANDA) | September 6, 2016 |
| Advagen Pharma Ltd | 4 | capsule, extended release | Generic drugs (ANDA) | March 20, 2020 |
| Sun Pharmaceutical Industries, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | February 15, 2019 |
| Alembic Pharmaceuticals Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | June 10, 2024 |
| Alembic Pharmaceuticals Limited | 3 | capsule, extended release | Generic drugs (ANDA) | June 10, 2024 |
| American Health Packaging | 3 | capsule, extended release | Generic drugs (ANDA) | June 3, 2014 |
| Annora Pharma Private Limited | 3 | capsule, extended release | Generic drugs (ANDA) | July 8, 2019 |
| Asclemed USA, Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | November 23, 2011 |
| AvKARE | 3 | capsule, extended release | Generic drugs (ANDA) | July 10, 2013 |
| AvPAK | 3 | capsule, extended release | Generic drugs (ANDA) | February 25, 2025 |
| Camber Pharmaceuticals, Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | July 8, 2019 |
| Dr. Reddy's Laboratories Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | September 9, 2024 |
| Epic Pharma, LLC | 3 | capsule, extended release | Generic drugs (ANDA) | September 7, 2022 |
| Granules Pharmaceuticals Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | September 25, 2023 |
| Macleods Pharmaceuticals Limited | 3 | capsule, extended release | Generic drugs (ANDA) | October 6, 2017 |
| Major Pharmaceuticals | 3 | capsule, extended release | Generic drugs (ANDA) | October 8, 2025 |
| Marlex Pharmaceuticals, Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | August 1, 2025 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 3 | capsule, extended release; tablet | Generic drugs (ANDA) | September 25, 2023 |
| Nivagen Pharmaceuticals, Inc. | 3 | tablet, extended release | Generic drugs (ANDA) | September 6, 2019 |
| NorthStar RxLLC | 3 | capsule, extended release | Generic drugs (ANDA) | June 1, 2026 |
| Northwind Health Company, LLC | 3 | tablet; capsule, extended release | Generic drugs (ANDA) | May 2, 2023 |
| Proficient Rx LP | 3 | capsule, extended release | Generic drugs (ANDA) | July 8, 2019 |
| Proficient Rx LP | 3 | capsule, extended release | Generic drugs (ANDA) | July 1, 2010 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 3 | capsule, extended release | Generic drugs (ANDA) | July 28, 2026 |
| Quallent Pharmaceuticals Health LLC | 3 | capsule, extended release | Generic drugs (ANDA) | November 21, 2022 |
| Viatris Specialty LLC | 3 | capsule, extended release | New drug applications (NDA) | October 30, 2024 |
| Zydus Lifesciences Limited | 3 | capsule, extended release | Generic drugs (ANDA) | May 18, 2023 |
| Zydus Pharmaceuticals USA Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | May 18, 2023 |
| Zydus Pharmaceuticals USA Inc. | 3 | capsule, extended release | Generic drugs (ANDA) | June 1, 2011 |
| QPharma, Inc. | 2 | capsule, extended release | Generic drugs (ANDA) | June 1, 2011 |
| Westminster Pharmaceuticals, LLC | 2 | tablet, extended release | Generic drugs (ANDA) | November 18, 2025 |
| Cardinal Health 107, LLC | 1 | capsule, extended release | Generic drugs (ANDA) | March 23, 2026 |
| Chartwell RX, LLC | 1 | tablet | Generic drugs (ANDA) | December 26, 2019 |
| Proficient Rx LP | 1 | capsule, extended release | Generic drugs (ANDA) | November 23, 2011 |
| St. Mary's Medical Park Pharmacy | 1 | capsule, extended release | Generic drugs (ANDA) | June 1, 2011 |
| Trigen Laboratories, LLC | 1 | tablet, extended release | Authorized generics (NDA) | April 29, 2010 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 159 | 74.6% |
| Tablet | 43 | 20.2% |
| Tablet, extended release | 11 | 5.2% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 208 | 97.7% |
| New drug applications (NDA) | 3 | 1.4% |
| Authorized generics (NDA) | 2 | 0.9% |
Pharmacologic classes
| Class | Products |
|---|---|
| Serotonin and Norepinephrine Reuptake Inhibitor | 213 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.